MBX Biosciences (MBX) Competitors $18.96 -1.04 (-5.20%) Closing price 09/23/2025 04:00 PM EasternExtended Trading$19.29 +0.33 (+1.74%) As of 09/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock MBX vs. NTLA, EVO, SNDX, STOK, AMPH, RCUS, PHVS, TRML, GPCR, and DNTHShould you be buying MBX Biosciences stock or one of its competitors? The main competitors of MBX Biosciences include Intellia Therapeutics (NTLA), Evotec (EVO), Syndax Pharmaceuticals (SNDX), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Arcus Biosciences (RCUS), Pharvaris (PHVS), Tourmaline Bio (TRML), Structure Therapeutics (GPCR), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. MBX Biosciences vs. Its Competitors Intellia Therapeutics Evotec Syndax Pharmaceuticals Stoke Therapeutics Amphastar Pharmaceuticals Arcus Biosciences Pharvaris Tourmaline Bio Structure Therapeutics Dianthus Therapeutics Intellia Therapeutics (NASDAQ:NTLA) and MBX Biosciences (NYSE:MBX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership. Do institutionals & insiders hold more shares of NTLA or MBX? 88.8% of Intellia Therapeutics shares are held by institutional investors. 3.1% of Intellia Therapeutics shares are held by company insiders. Comparatively, 52.2% of MBX Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is NTLA or MBX more profitable? MBX Biosciences has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -908.48%. MBX Biosciences' return on equity of 0.00% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Intellia Therapeutics-908.48% -57.48% -45.04% MBX Biosciences N/A N/A N/A Do analysts rate NTLA or MBX? Intellia Therapeutics presently has a consensus price target of $27.39, suggesting a potential upside of 60.36%. MBX Biosciences has a consensus price target of $37.63, suggesting a potential upside of 98.44%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe MBX Biosciences is more favorable than Intellia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intellia Therapeutics 1 Sell rating(s) 7 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.53MBX Biosciences 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, NTLA or MBX? MBX Biosciences has lower revenue, but higher earnings than Intellia Therapeutics. MBX Biosciences is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntellia Therapeutics$57.88M31.68-$519.02M-$4.69-3.64MBX BiosciencesN/AN/AN/A-$4.54-4.18 Does the media favor NTLA or MBX? In the previous week, Intellia Therapeutics had 4 more articles in the media than MBX Biosciences. MarketBeat recorded 18 mentions for Intellia Therapeutics and 14 mentions for MBX Biosciences. Intellia Therapeutics' average media sentiment score of 0.63 beat MBX Biosciences' score of 0.53 indicating that Intellia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intellia Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 4 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryMBX Biosciences beats Intellia Therapeutics on 7 of the 13 factors compared between the two stocks. Get MBX Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBX vs. The Competition Export to ExcelMetricMBX BiosciencesPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$636.94M$873.86M$5.76B$21.71BDividend YieldN/A4.84%5.53%3.52%P/E Ratio-4.181.1976.4329.86Price / SalesN/A114.73473.3162.12Price / CashN/A17.6437.4624.72Price / BookN/A6.4613.614.59Net IncomeN/A-$5.56M$3.29B$1.00B7 Day Performance90.74%0.53%1.87%0.64%1 Month Performance32.31%5.75%4.03%2.77%1 Year Performance-17.53%25.85%77.41%14.49% MBX Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBXMBX Biosciences2.8873 of 5 stars$18.96-5.2%$37.63+98.4%-14.9%$636.94MN/A-4.1836Trending NewsAnalyst ForecastHigh Trading VolumeNTLAIntellia Therapeutics4.4552 of 5 stars$12.43+7.4%$27.11+118.2%-20.4%$1.33B$52.86M-2.64600EVOEvotec1.7469 of 5 stars$3.68+5.0%$5.40+46.9%+12.2%$1.31B$777.33M0.004,827News CoverageGap DownSNDXSyndax Pharmaceuticals3.8316 of 5 stars$15.10-4.7%$39.22+159.8%-17.2%$1.30B$23.68M-3.89110Positive NewsSTOKStoke Therapeutics3.5869 of 5 stars$23.57+0.7%$25.57+8.5%+70.5%$1.29B$199.89M27.71100Positive NewsAMPHAmphastar Pharmaceuticals4.1053 of 5 stars$27.06-0.8%$31.60+16.8%-43.6%$1.26B$731.97M10.162,028Positive NewsRCUSArcus Biosciences1.9192 of 5 stars$11.79+1.8%$21.14+79.4%-21.0%$1.25B$262M-3.72500Positive NewsPHVSPharvaris2.443 of 5 stars$23.70+1.4%$34.00+43.5%+30.5%$1.24BN/A-7.0530TRMLTourmaline Bio0.823 of 5 stars$47.70+0.1%$45.65-4.3%+107.5%$1.23BN/A-13.9144GPCRStructure Therapeutics3.2778 of 5 stars$21.15+4.7%$75.71+258.0%-43.3%$1.22BN/A-20.14136DNTHDianthus Therapeutics2.7788 of 5 stars$37.81+2.1%$61.57+62.8%+44.7%$1.22B$4.85M-11.6480 Related Companies and Tools Related Companies Intellia Therapeutics Competitors Evotec Competitors Syndax Pharmaceuticals Competitors Stoke Therapeutics Competitors Amphastar Pharmaceuticals Competitors Arcus Biosciences Competitors Pharvaris Competitors Tourmaline Bio Competitors Structure Therapeutics Competitors Dianthus Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:MBX) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredIs This Nvidia’s Next Big Invention? (Picture Inside)Nvidia gave investors a chance to make more than 150 times their money with its AI chips known as graphic proc...InvestorPlace | SponsoredAnother gold high? Here’s the move Wall Street is missing …Gold has surged past $3,600 an ounce, up 45% in the last year, but Weiss Ratings analyst Sean Brodrick says th...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MBX Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MBX Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
